O. Kostek Et Al. , "Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer," CLINICAL & TRANSLATIONAL ONCOLOGY , vol.21, no.11, pp.1510-1517, 2019
Kostek, O. Et Al. 2019. Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer. CLINICAL & TRANSLATIONAL ONCOLOGY , vol.21, no.11 , 1510-1517.
Kostek, O., Demircan, N. C., Gokyer, A., Kucukarda, A., Sunal, B. S., Hacioglu, M. B., ... Eslame, H.(2019). Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer. CLINICAL & TRANSLATIONAL ONCOLOGY , vol.21, no.11, 1510-1517.
Kostek, OSMAN Et Al. "Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer," CLINICAL & TRANSLATIONAL ONCOLOGY , vol.21, no.11, 1510-1517, 2019
Kostek, OSMAN Et Al. "Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer." CLINICAL & TRANSLATIONAL ONCOLOGY , vol.21, no.11, pp.1510-1517, 2019
Kostek, O. Et Al. (2019) . "Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer." CLINICAL & TRANSLATIONAL ONCOLOGY , vol.21, no.11, pp.1510-1517.
@article{article, author={OSMAN KÖSTEK Et Al. }, title={Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer}, journal={CLINICAL & TRANSLATIONAL ONCOLOGY}, year=2019, pages={1510-1517} }